Liminal BioSciences gets $5m for subsidiary with more to come
Cambridge-Canadian biopharma Liminal BioSciences Inc has sold its plasma-derived therapeutics manufacturing subsidiary to Italian company Kedrion, anchored in Tuscany.
The manufacturing facility is operated through Liminal BioSciences’ subsidiary, Prometic Bioproduction Inc in Quebec.
Liminal received $5 million and will also be entitled to receive 70 per cent of the net proceeds from a sale of the Rare Pediatric Disease Priority Review Voucher by Prometic Biotherapeutics Inc.
Liminal BioSciences is focused on discovering, developing and commercialising novel treatments for patients suffering from diseases of unmet medical need, primarily related to fibrosis, including respiratory, liver and kidney diseases.
In December 2020, Liminal’s lead small molecule product candidate, fezagepras (PBI-4050), entered a Phase 1 clinical trial in in the UK to evaluate multiple-ascending doses in normal healthy volunteers, at daily dose exposures higher than those evaluated in previously completed Phase 2 clinical trials.
The company expects that a full analysis of the complete PK data set from the phase 1 multi-ascending dose clinical trial will help determine the choice of any other potential indication(s) for further development of fezagepras.
No dose-limiting adverse events or other potential safety signals have been observed in the Phase 1 multiple-ascending dose clinical trial to date, the company says.
Liminal has Cambridge UK operations at Iconix Park in Sawston.